DF
Therapeutic Areas
Race Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bisantrene (RC220) | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 2 |
Leadership Team at Race Oncology
PL
Philip Lynch
Executive Director & Chief Executive Officer
DD
Dr. Daniel Tillett
Chief Scientific Officer
DD
Dr. David Fuller
Non-Executive Chairman
DJ
Dr. James Garner
Chief Medical Officer
DP
Dr. Peter Molloy
Non-Executive Director
DG
Dr. Gabriel Kremmidiotis
Former Chief Executive Officer